Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVLida Kalmanti, M. C. Muller, Christian Dietz et al.|Leukemia|2015Cited by 274
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaThomas Ernst, M. C. Muller|Haematologica|2008Cited by 50